Background: This review aims to qualitatively summarize the published real-world evidence (RWE) for CDK4/6 inhibitors (CDK4/6i) approved for treating HR+, HER2-negative advanced/metastatic breast cancer (HR+/HER2- a/mBC). Materials & methods: A systematic literature review was conducted to identify RWE studies of CDK4/6i in HR+/HER2- a/mBC published from 2015 to 2019. Results: This review identified 114 studies, of which 85 were only presented at scientific conferences. Most RWE studies investigated palbociclib and demonstrated improved outcomes. There are limited long-term and comparative data between CDK4/6i and endocrine monotherapy, and within the CDK4/6i class. Conclusion: Available RWE suggests that CDK4/6i are associated with improved outcomes in HR+/HER2- a/mBC, although additional studies with longer follow-up periods are needed.
Background: This review aims to qualitatively summarize the published real-world evidence (RWE) for CDK4/6 inhibitors (CDK4/6i) approved for treating HR+, HER2-negative advanced/metastatic breast cancer (HR+/HER2- a/mBC). Materials & methods: A systematic literature review was conducted to identify RWE studies of CDK4/6i in HR+/HER2- a/mBC published from 2015 to 2019. Results: This review identified 114 studies, of which 85 were only presented at scientific conferences. Most RWE studies investigated palbociclib and demonstrated improved outcomes. There are limited long-term and comparative data between CDK4/6i and endocrine monotherapy, and within the CDK4/6i class. Conclusion: Available RWE suggests that CDK4/6i are associated with improved outcomes in HR+/HER2- a/mBC, although additional studies with longer follow-up periods are needed.
Authors: Tobias Engler; Peter A Fasching; Diana Lüftner; Andreas D Hartkopf; Volkmar Müller; Hans-Christian Kolberg; Peyman Hadji; Hans Tesch; Lothar Häberle; Johannes Ettl; Markus Wallwiener; Matthias W Beckmann; Alexander Hein; Erik Belleville; Sabrina Uhrig; Pauline Wimberger; Carsten Hielscher; Christian M Kurbacher; Rachel Wuerstlein; Michael Untch; Florin-Andrei Taran; Hans-Martin Enzinger; Petra Krabisch; Manfred Welslau; Michael Maasberg; Dirk Hempel; Michael P Lux; Laura L Michel; Wolfgang Janni; Diethelm Wallwiener; Sara Y Brucker; Tanja N Fehm; Andreas Schneeweiss Journal: Geburtshilfe Frauenheilkd Date: 2022-07-12 Impact factor: 2.754
Authors: Elizabeth R Smith; Marilyn Huang; Matthew P Schlumbrecht; Sophia H L George; Xiang-Xi Xu Journal: Front Oncol Date: 2022-09-15 Impact factor: 5.738
Authors: Hope S Rugo; Adam Brufsky; Xianchen Liu; Benjamin Li; Lynn McRoy; Connie Chen; Rachel M Layman; Massimo Cristofanilli; Mylin A Torres; Giuseppe Curigliano; Richard S Finn; Angela DeMichele Journal: NPJ Breast Cancer Date: 2022-10-11